Core Concept: What is SELEX? SELEX (Systematic Evolution of Ligands by EXponential Enrichment) is an iterative, in vitro selection process. It starts with a vast, random library of oligonucleotides (10^14 - 10^15 unique sequences) and, over multiple rounds, enriches for those that bind to the target. Standard Multi-Round SELEX Screening Service Workflow A full-service provider will typically manage the entire process, which can be broken down into key phases: Phase 1: Project Design & Target Preparation Target Consultation: Defining the target (e.g., protein, small molecule, cell, virus). Critical discussion of target purity, immobilization strategy, and selection conditions (buffer, temperature, counter-selection). Library Design: Selection of a random library (e.g., 40-nt random core with fixed primer sites). Options include DNA, RNA (requiring reverse transcription), or modified libraries (e.g., with 2'-F pyrimidines for nuclease resistance). Immobilization Strategy: The service provider will choose the best method: Immobilized Target: (Most common for proteins) Binding target to beads (streptavidin, Ni-NTA for His-tag) or columns. Counter-Selection: Using negative control surfaces (e.g., blank beads, related but undesired proteins) to subtract non-specific binders. Phase 2: The SELEX Cycle (Repeated 8-15 Rounds) This is the core iterative screening process. Each round consists of: Incubation: The oligonucleotide library is incubated with the target under defined conditions. Partitioning: Separation of…
Aptamer Screening via HT-SELEX (High-Throughput Systematic Evolution of Ligands by Exponential Enrichment) is the modern, powerful method for discovering aptamers. Let's break down what this service entails, its process, advantages, and key considerations. What is an Aptamer? First, a quick reminder: Aptamers are single-stranded DNA or RNA oligonucleotides that bind to a specific target molecule (proteins, small molecules, cells, viruses) with high affinity and specificity, analogous to antibodies. They are often called "chemical antibodies." What is HT-SELEX? Traditional SELEX is iterative and low-throughput. HT-SELEX supercharges this process by integrating: Next-Generation Sequencing (NGS): To analyze the entire aptamer pool at each round. Advanced Bioinformatics: To identify binding motifs and track enrichment. Automation: Using robotics for partitioning (e.g., magnetic beads, microfluidics) to increase throughput and reproducibility. This results in a faster, more efficient, and data-driven screening process. Standard HT-SELEX Service Workflow A typical service provider will follow these steps: 1. Project Design & Library Synthesis Target Preparation: You provide the target (recombinant protein, small molecule conjugate, whole cell, etc.). Its purity and stability are critical. Library Design: A randomized oligonucleotide library is synthesized (typically 10^14 - 10^15 unique sequences). Libraries can be DNA, RNA, or modified nucleotides (e.g., SOMAmers) for enhanced stability and affinity. 2. The Selection Rounds (Cycles of…
Core Concept of NGS-SELEX Traditional SELEX uses a few rounds of selection and cloning/Sanger sequencing of a handful of clones. NGS-SELEX performs deep sequencing (millions to billions of reads) at every selection round. This allows you to: Track the entire evolution of the oligonucleotide pool in real-time. Identify enriched sequences and families early. Perform sophisticated bioinformatics analysis to find winners, not just rely on final round abundance. Dramatically reduce the number of selection rounds needed (often 3-6 rounds instead of 8-15). Standard Service Workflow A full-service provider would typically offer the following pipeline: 1. Project Design & Library Synthesis Consultation: Target properties (protein, small molecule, cell), desired aptamer properties (Kd, specificity, buffer conditions). Library Design: Standard (40-60 nt random region) or custom (doped libraries, modified nucleotides like 2'-F, 2'-OMe, SOMAmers). Primer & Library Synthesis: Providing the initial, highly diverse DNA or RNA library (10^14 - 10^15 unique sequences). 2. SELEX Selection Immobilization: Immobilizing the target (on beads, column, plate) or using solution-based techniques (capture-SELEX, toggle-SELEX). Counter-Selection: Including steps to remove binders to immobilization matrix or off-targets. Stringency Control: Increasing selection pressure over rounds (e.g., reduced target concentration, increased wash stringency). Amplification: Careful PCR (with optimization to minimize bias) to regenerate the pool for the next round. 3. NGS & Core Bioinformatics Sample Preparation: Preparing sequencing…
What is Counter-SELEX? First, a quick recap of SELEX (Systematic Evolution of Ligands by EXponential Enrichment): SELEX is an iterative process to isolate specific DNA or RNA aptamers from a vast random library (10^14 - 10^15 sequences) that bind tightly to a target molecule (e.g., a protein, small molecule, cell). Counter-SELEX is a powerful refinement to this process. Its core purpose is to improve specificity by negative selection. How it works: During or between rounds of positive selection (binding to the desired target), the oligonucleotide pool is exposed to one or more counter-targets. The Goal: Sequences that bind to these counter-targets are deliberately removed or depleted from the pool. Only sequences that bind specifically to the desired target and not to the closely related counter-targets are carried forward. Common Counter-Targets: Structural analogs: For a small-molecule drug, you might use its inactive metabolite or a similar drug from the same class. Protein isoforms or family members: To develop an aptamer for a specific kinase, you'd use other kinases from the same family as counter-targets. Immobilization matrix: If the target is immobilized on beads, pre-incubating the library with "blank" beads removes matrix binders. Related cell types: For a cell-specific aptamer (e.g., cancer vs. healthy), the healthy cells are used as the counter-target. What Does a…
What is Subtractive SELEX? It is a specialized version of SELEX used to generate aptamers (single-stranded DNA or RNA oligonucleotides) that bind with high affinity and specificity to a target of interest (e.g., a protein, cell, small molecule) while actively excluding binding to closely related non-targets (e.g., a non-pathogenic vs. pathogenic strain, a healthy vs. cancerous cell, or a target in a complex mixture). The "subtractive" step removes sequences that bind to unwanted counter-targets, ensuring the final aptamer pool is highly specific. Core Workflow of a Subtractive SELEX Service A typical service follows these key stages: 1. Project Design & Library Synthesis Client Consultation: Defining the target of interest (e.g., recombinant protein, whole cell) and the critical counter-target(s) for subtraction (e.g., isotype control protein, non-target cell line). Library Design: A service provider synthesizes a vast random-sequence oligonucleotide library (typically 10^14 - 10^15 unique sequences) flanked by constant primer regions. 2. The Subtractive SELEX Cycle (Repeated 8-15 Rounds) This is the iterative heart of the service: * a. Negative Selection (Subtraction): The oligonucleotide pool is incubated with the counter-target (or complex background, like serum). Sequences that bind to this unwanted material are discarded. * b. Positive Selection: The unbound sequences from (a) are then incubated with the target of interest. The bound sequences are recovered. * c. Washing: Non-specific or weakly bound sequences are washed away.…
What are Aptamers? Aptamers are short, single-stranded DNA or RNA oligonucleotides (typically 20-80 nucleotides) that fold into specific three-dimensional shapes, enabling them to bind to target molecules with high affinity and specificity. They are often called "chemical antibodies." The process of creating them is called SELEX (Systematic Evolution of Ligands by EXponential enrichment), which iteratively selects aptamers from vast random-sequence libraries against a desired target (e.g., a protein, small molecule, or even a whole cell). Key Advantages of Aptamers as Therapeutics Compared to traditional protein-based biologics like antibodies, aptamers offer several compelling benefits: High Specificity & Affinity: Can distinguish between closely related targets (e.g., different protein isoforms). Small Size: Typically 8-25 kDa, much smaller than antibodies (~150 kDa). This can improve tissue penetration. Full Chemical Synthesis: Produced in vitro via chemical synthesis, eliminating batch-to-batch variability and the need for biological systems (cells or animals). This makes manufacturing scalable and consistent. Low Immunogenicity: Being nucleic acids, they are generally less likely to trigger immune reactions than foreign proteins. Excellent Stability: DNA aptamers, in particular, are thermally stable and can be stored easily. Stability in biological fluids can be engineered. Ease of Modification: Can be chemically modified to enhance stability (e.g., resist nucleases), prolong half-life (e.g., PEGylation), or add functional groups…
Aptamers are single-stranded oligonucleotides that fold into defined architectures and bind to targets such as proteins. In binding proteins they often inhibit protein–protein interactions and thereby may elicit therapeutic effects such as antagonism. Aptamers are discovered using SELEX (systematic evolution of ligands by exponential enrichment), a directed in vitro evolution technique in which large libraries of degenerate oligonucleotides are iteratively and alternately partitioned for target binding. They are then amplified enzymatically until functional sequences are identified by the sequencing of cloned individuals. For most therapeutic purposes, aptamers are truncated to reduce synthesis costs, modified at the sugars and capped at their termini to increase nuclease resistance, and conjugated to polyethylene glycol or another entity to reduce renal filtration rates. The first aptamer approved for a therapeutic application was pegaptanib sodium (Macugen; Pfizer/Eyetech), which was approved in 2004 by the US Food and Drug Administration for macular degeneration. Eight other aptamers are currently undergoing clinical evaluation for various haematology, oncology, ocular and inflammatory indications. Aptamers are ultimately chemically synthesized in a readily scalable process in which specific conjugation points are introduced with defined stereochemistry. Unlike some protein therapeutics, aptamers do not elicit antibodies, and because aptamers generally contain sugars modified at their 2′-positions,…
The unique secondary and tertiary structures of aptamers provide the specificity to detect even small structural changes in the target molecule, including the presence or absence of methyl or hydroxyl groups or differences in enantiomeric configurations. Aptamers that bind specific targets are identified through a process known as Systematic Evolution of Ligands by Exponential enrichment (SELEX) in which binding molecules are selected from a large and diverse library of nucleic acids (either DNAs or RNAs). In this process, the nucleic acid library is incubated with the target molecule. Non-binding nucleic acids are then washed away, leaving behind only the molecules that have a capacity to bind to the target molecule. The nucleic acids that are not washed away are then used to create a new library of nucleic acids that is enriched for the subset that binds the desired target. Repeating this selection-cycle on each subsequent library with increasing stringency of binding (e.g. lower concentration of target), ensures that nucleic acids that bind to the target with both high specificity and high affinity are enriched. Aptamers are short, single-stranded oligonucleotides (DNA or RNA) that bind to specific target molecules with high affinity and specificity. They are often called "chemical antibodies."…
The Approved Drug: Pegcetacoplan (Empaveli/Syfovre) This is actually a single aptamer molecule with two distinct FDA approvals for different diseases: Paroxysmal Nocturnal Hemoglobinuria (PNH): Approved in 2021 under the brand name Empaveli. It is a complement C3 inhibitor used to treat adults with PNH. Geographic Atrophy (GA): Approved in 2023 under the brand name Syfovre. It is used to treat GA secondary to age-related macular degeneration (AMD). How it works: Pegcetacoplan is a pegylated (attached to a polyethylene glycol chain for longer circulation) aptamer that binds specifically to complement protein C3. By inhibiting C3, it suppresses a central part of the body's complement immune system, which is overactive in both PNH and GA. Important Context and Other Notable Aptamers First-Ever Approval: The first aptamer therapeutic ever approved was Pegaptanib (Macugen) in 2004 for wet AMD. It targets VEGF. While it was a pioneering drug, it has since been largely superseded by more effective antibody-based treatments (like ranibizumab and aflibercept). It is still approved but rarely used. International Approvals: Another significant aptamer is Avacincaptad pegol (Izervay), which was also FDA-approved for Geographic Atrophy in 2023. It works by inhibiting complement C5. Aptamers in Diagnostics: While therapeutic aptamers are rare, aptamers are widely used in research and diagnostic tools. A famous example is the SOMAscan platform, which uses thousands of Slow Off-rate Modified…
Antibody: A large, Y-shaped protein produced naturally by the immune system (B cells) in response to a foreign substance (antigen). It is a biological molecule. Aptamer: A short, single-stranded piece of DNA or RNA (or modified nucleotides) that is artificially engineered in a lab to bind to a specific target. It is a chemical molecule. Key Differences at a Glance Feature Antibody Aptamer Chemical Nature Protein (IgG, etc.) Nucleic Acid (DNA or RNA) Origin Biological (from animals) Chemical (SELEX process in vitro) Size Large (~150 kDa) Small (~10-30 kDa) Production Requires animal immunization or cell culture. Batch-to-batch variability possible. Synthetic, produced by chemical synthesis. Highly reproducible. Targets Primarily immunogenic targets (proteins, pathogens). Limited to targets that elicit an immune response. Extremely broad: ions, small molecules, proteins, cells, viruses, tissues. Can target toxins or non-immunogenic substances. Stability Sensitive to temperature (often requires refrigeration), pH, and proteases. Can denature. Thermally stable, can be renatured after denaturation. Resistant to harsh conditions (pH, organic solvents). Modification Difficult to modify chemically without affecting function. Site-specific conjugation is complex. Easy to chemically modify with reporters, drugs, or linkers at precise locations. Immunogenicity Can itself trigger an immune response (especially non-human antibodies). Generally low immunogenicity, but can be designed to be non-immunogenic. Cost…
